168 related articles for article (PubMed ID: 19718766)
1. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
Chachad S; Gogtay J; Malhotra G; Purandare S
J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
[No Abstract] [Full Text] [Related]
2. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
Rackley RJ
J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
[No Abstract] [Full Text] [Related]
3. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.
Garren KW; Rahim S; Marsh K; Morris JB
J Pharm Sci; 2010 Feb; 99(2):626-31. PubMed ID: 19230020
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
de Kanter CT; Colbers EP; Fillekes Q; Hoitsma A; Burger DM
J Antimicrob Chemother; 2010 Mar; 65(3):538-42. PubMed ID: 20056686
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
7. Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
Morello J; Soriano V; Blanco F; Rubio AJ; Jiménez-Nácher I; Rodríguez-Nóvoa S
Drug Metab Lett; 2009 Apr; 3(2):67-9. PubMed ID: 19601866
[TBL] [Abstract][Full Text] [Related]
8. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
[No Abstract] [Full Text] [Related]
9. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
Ramautarsing RA; van der Lugt J; Gorowara M; Sophonphan J; Ananworanich J; Lange JM; Burger DM; Phanuphak P; Ruxthungtham K; Avihingsanon A
Antivir Ther; 2013; 18(2):249-52. PubMed ID: 22908131
[TBL] [Abstract][Full Text] [Related]
14. [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
MMW Fortschr Med; 2001 Apr; 143 Suppl 1():96-7. PubMed ID: 11373795
[No Abstract] [Full Text] [Related]
15. Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
Ramautarsing RA; van der Lugt J; Gorowara M; Wongsabut J; Khongpetch C; Phanuphak P; Ananworanich J; Lange JM; Burger DM; Ruxrungtham K; Avihingsanon A
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):55-8. PubMed ID: 22027875
[TBL] [Abstract][Full Text] [Related]
16. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
17. Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Harris M; Alexander C; O'Shaughnessy M; Montaner JS
AIDS; 2002 Mar; 16(5):798-9. PubMed ID: 11964540
[No Abstract] [Full Text] [Related]
18. Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir.
Meynard JL; Lacombe K; Poirier JM; Massot O; Lefebvre B; Bouchaud O; Guiard-Schmidt JB; Martinez A; Benlian P; Girard PM
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):311-6. PubMed ID: 19015293
[TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
Kaplan SS; Hicks CB
Expert Opin Pharmacother; 2005 Aug; 6(9):1573-85. PubMed ID: 16086645
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
la Porte CJ; Schippers EF; van der Ende ME; Koopmans PP; Blok WL; Kauffmann RH; Kroon FP; Burger DM
AIDS; 2005 Jul; 19(10):1105-7. PubMed ID: 15958844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
